Despite recent policy uncertainties, Wuxi Biologics’ focus on its US operations will continue to pay off in 2025, with the US accounting for the majority of the record number of projects the CRDMO secured last year.
Throughout 2025, the China-based contractor won an impressive 209 new integrated projects, compared to 148 added in 2024, bringing the program total to 945, Wuxi Bio said in its full-year earnings report on Tuesday. About half of these new programs come from the US, which the company says reflects “strong momentum in the US biopharmaceutical sector.”
The overall portion of the new project included six late-stage programs, the company added. About two-thirds of WuXi Biologics’ 2025 contracts focused on bispecifics and antibody-drug conjugates (ADCs).
Overall, the manufacturer and researchers increased sales last year to 21.8 billion Chinese yuan (about $3.2 billion), an increase of 16.7% compared to 2024.
In comparison, WuXi Bio’s total sales in 2024 were 18.7 billion yuan (valued at around $2.6 billion at the time), registering 9.6% growth over the past 12 months. At the time, WuXi Bio CEO Chris Chen said he expected his company to achieve “accelerated and profitable growth from 2025 onwards.”
In the latest report on the company’s sales performance, Mr. Chen pointed out that WuXi Bio’s integration of R&D and manufacturing in all stages of the project gives CRDMO a unique advantage. The company continues to benefit from increased customer interest in complex biologics, such as bispecific and multispecific and ADCs, and continues to benefit from its underlying monoclonal antibody business, he explained.
Regarding the factors driving WuXi Bio’s 2025 performance, the company also highlighted its production capacity expansion by strengthening its manufacturing operations in Europe last year. CRDMO highlighted its global dual sourcing strategy and indicated progress or completion of production expansion projects in the US, Singapore and Qatar as well in 2025.
Last year’s manufacturing industry revenue particularly increased by more than 26%, WuXi Bio added.
As of the end of last year, WuXi Bio had a total work balance of $23.7 billion, of which service balance was $11.5 billion and potential milestones were $12.2 billion, the company announced on Tuesday.
Wuxi Bio’s strong performance, particularly in the United States, suggests that the company has largely avoided pressure from U.S. national security-focused policy proposals that previously created uncertainty for Wuxi Bio, its sibling Wuxi Uptech, and several other Chinese companies.
WuXi Bio, WuXi AppTec, and three other companies (BGI Group, MGI, and Complete Genomics) were initially named in the BioSecure Act, which aims to limit the ability of certain “concerned” companies to cooperate with U.S. government agencies and businesses, but the latest bill takes a more measured approach in how it targets the companies, and does not name WuXi Biologics.
Wuxi Biologics reported sales a day after its sister company Wuxi AppTec recorded a 15.8% increase in revenue to 45.56 billion yuan ($6.6 billion) in 2025.
WuXi AppTec also provides a variety of contract research and development and manufacturing services, and is currently expected to have total revenue of 51.3 billion yuan to 53 billion yuan in 2026, with sales growth of 18% to 22%, respectively.
